Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha

Gut

Volumn 40, Issue 5, 1997, Pages 628-633

  Watkins, P E ^a,c   Warren, B F ^a   Stephens, S ^b   Ward, P ^b   Foulkes, R ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UCB PHARMA   (Belgium)

^c DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

Antibody to tumour necrosis factor ; Cottontop tamarin; Ulcerative colitis

Indexed keywords

MONOCLONAL ANTIBODY CDP 571; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NONHUMAN; PRIMATE; PRIORITY JOURNAL; ULCERATIVE COLITIS;

EID: 0030947668     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.40.5.628     Document Type: Article

References (33)

1. Sanderson JD, Moss MT, Tizard MLV, Hermon-Taylor J. Mycobacterium paratuberculosis DNA in Crohn's disease tissue. Gut 1992; 33: 890-6.
2. Wakefield AJ, Pittilo RM, Sim R, Costy SL, Stephenson JR, Dhillon AP, et al. Evidence of persistent measles virus infection in Crohn's disease. J Med Virol 1993; 39: 345-53.
3. Thompson NP, Montgomery SM, Pounder RE, Wakefield AJ. Is measles vaccination a risk factor for inflammatory bowel disease? Lancet 1995; 345: 1071-4.
4. Wakefield AJ, Sawyerr AM, Dhillon P, Pittilo RM, Rowles PM, Lewis AM, et al. Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet 1989; ii: 773-5.
5. Rotter JI, Yang H. Delineating the major aetiological risk factors for IBD: the genetic susceptibilities. In: Scholmerich J, Kruis W, Goebell H, Hohenberger H, Gross V, eds. Inflammatory bowel diseases. London: Kluwer Academic Publishers, 1993.
6. Gelbmann CM, Barrett KE. Role of inflammatory cell types. In: Scholmerich J, Kruis W, Goebell H, Hohenberger H, Gross V, eds. Inflammatory bowel diseases. London: Kluwer Academic Publishers, 1903.
7. Stevens C, Walz G, Singaram C, Lipman ML, Zanker B, Muggia A, et al. Tumour necrosis factor alpha, interleukin-1β, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 1992; 37: 818-26.
8. Sun X, Caplan MS, Liu Y, Hsueh W. Endotoxin-resistant mice are protected from PAF-induced bowel injury and death. Dig Dis Sci 1995; 40: 495-502.
9. Bruin KF, Hommes DW, Jansen J, van Deventer SJM. Modulation of cytokine release from human monocytes by drugs used in the therapy of inflammatory bowel disease [abstract]. Gastroenterology 1993; 104 (suppl 4): A674.
10. Tracey KJ, Beutler K, Lowry SF, Merryweather J, Wolpe S, Milsark IW, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470-4.
11. Maini RN, Brennan FM, Williams R, Chu CQ, Cope AP, Gibbons D, et al. TNFα in rheumatoid arthritis and prospects of anti-TNF therapy. Clin Exp Rheumatol 1993; 11 (suppl 8): S173-5.
12. Elliott M, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10.
13. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991; 32: 913-7.
14. Murch SH, Breagger CP, Walker-Smith JA, MacDonald TT. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993; 34: 1705-9.
15. Breagger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339: 89-91.
16. Warren BF, Watkins PE. Animal models of inflammatory bowel disease. J Pathol 1994; 172: 313-6.
17. Ward PS, Woodger SR, Bodmer M, Foulkes R. Anti-tumour necrosis factor alpha monoclonal antibodies are therapeutically effective in a model of colonic inflammation. Br J Pharmacol 1993; 110: 77P.
18. Madara J, Podolsky DK, King NW, Sehgal PK, Moore R, Winter HB. Characterization of spontaneous colitis in cottontop tamarins (Saguinus oedipus) and its response to sulfasalazine. Gastroenterology 1985; 88: 13-9.
19. Watkins PE, Warren BF, Silver IA. The treatment of ulcerative colitis in the cottontop tamarin. Abstract 726. Proceedings of 14th Congress of the International Primatological Society; 1992 Aug 16-21; Strasbourg.
20. Kirkwood JK, Pearson GR, Epstein MA. Adenocarcinoma of the large bowel and colitis in cottontop tamarins. J Comp Pathol 1986; 96: 507-15.
21. Warren BF, Henke M, Clapp N. Extra-intestinal manifestations of cottontop tamarin colitis. In: Clapp N, ed. A primate model for the study of colitis and colonic carcinoma. Boca Raton, FL: CRC Press, 1993: 127-32.
22. Watkins PE, Foulkes R, Ward P, Stephens S, Warren BF. Faecal tumour necrosis factor alpha in cottontop tamarin colitis [abstract]. J Pathol 1993; 170: 364A.
23. Podolsky DF, Lobb R, King X, Benjamin CD, Pepinsky B, Sehgal P, et al. Attenuation of colitis in the cottontop tamarin by anti-α4 integrin monoclonal antibody. J Clin Invest 1993; 92: 372-80.
24. Kirkwood JK, Epstein MA, Terleckei AJ. Factors influencing population growth of a colony of cottontop tamarins. Lab Anim 1983; 17: 35-41.
25. Kirkwood JK, Epstein MA, Terleckei AJ, Underwood SJ. Rearing a second generation of cottontop tamarins (Saguinus oedipus oedipus) in captivity. Lab Anim 1985; 19: 269-72.
26. Warren BF, Rigby HS, Neumann C, Hall MJ, Mountford RA, Bradfield JWB. The role of multiple colonoscopic biopsies in longstanding ulcerative colitis [abstract]. J Pathol 1988; 155: 347A.
27. Stephens S, Emtage S, Vetterlein O, Chaplin L, Bebbington C, Nesbitt A, et al. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology 1995; 85: 668-74.
28. Fisher CJ, Opal SM, Dhainaut JF. Influence of anti-TNFα monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993; 21: 318-27.
29. Rankin ECC, Choy EHS, Kassimos D, Kingsley GH, Sopwith AM, Isenberg DA, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rhematoid arthritis. Br J Rheumatol 1995; 34: 334-42.
30. Elliott M, Maini RN, Feldman M, Long-Fox A, Charles P, Bijl H, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344: 1125-7.
31. Stephens S, Vetterlein O, Sopwith M. CDP571, an engineered antibody to human tumour necrosis factor. In: Antibody therapeutics. Boca Raton, FL: CRC Press, 1996.
32. van Dulleman HM, van Deventer SJH, Hommes DW, Bijl HA, Jansen J, Tytgat GNJ, el al. Treatment of Crohn's disease with anti-tumour necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129-35.
33. Evans RC, Clark L, Rhodes JM. Treatment of ulcerative colitis with an engineered human anti-TNFα antibody CDP571. Proceedings of 4th United European Gastroenterology Conference; 1995 Sept 17-21; Berlin. London: BMJ Publishing Group, 1995.